Generic drug: sulfur hexafluoride lipid-type A microspheres

Brand name: Lumason

What is Lumason (sulfur hexafluoride lipid-type A microspheres), and how does it work?

Lumason (sulfur hexafluoride lipid-type A microspheres) is an ultrasound contrast agent indicated for use in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms, and in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients.

What are the side effects of Lumason?

WARNING

SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres. Most serious reactions occur within 30 minutes of administration.

Assess all patients for the presence of any condition that precludes administration.

  • Always have resuscitation equipment and trained personnel readily available.

Common side effects of Lumason include:

What is the dosage for Lumason?

Important Administration Instructions

Do not administer Lumason by intra-arterial injection.

Recommended Dosage

Echocardiography

Adults

  • The recommended dose of Lumason after reconstitution is 2 mL administered as an intravenous bolus injection during echocardiography.
  • During a single examination, a second injection of 2 mL may be administered to prolong contrast enhancement.
  • Follow each Lumason injection with an intravenous flush using 5 mL of 0.9% Sodium Chloride Injection, USP.

Pediatric Patients

  • The recommended dose of Lumason after reconstitution in pediatric patients is 0.03 mL per kg administered as an intravenous injection during echocardiography.
  • During a single examination, a second injection of 0.03 mL per kg may be administered, if needed.
  • Do not exceed 2 mL per injection. Follow Lumason injection with an intravenous flush using 5 mL of 0.9% Sodium Chloride Injection, USP.
Ultrasonography Of The Liver

Adults

  • The recommended dose of Lumason after reconstitution in adult patients is 2.4 mL administered as an intravenous injection during ultrasonography of the liver.
  • During a single examination, a second injection of 2.4 mL may be administered, if needed.
  • Follow Lumason injection with an intravenous flush using 5 mL of 0.9% Sodium Chloride Injection, USP.

Pediatric Patients

  • The recommended dose of Lumason after reconstitution in pediatric patients is 0.03 mL per kg administered as an intravenous injection during ultrasonography of the liver.
  • During a single examination, a second injection of 0.03 mL per kg may be administered, if needed.
  • Do not exceed 2.4 mL per injection.
  • Follow Lumason injection with an intravenous flush of 0.9% Sodium Chloride Injection, USP.
Ultrasonography Of The Urinary Tract

Pediatric Patients

  • The recommended dose of Lumason after reconstitution is 1 mL.
  • The bladder may be refilled with 0.9% Sodium Chloride Injection, USP for a second cycle of voiding and imaging, without the need of a second Lumason administration.

What drugs interact with Lumason?

No information provided

Is Lumason safe to use while pregnant or breastfeeding?

  • There are no data with Lumason use in pregnant women to inform any drug-associated risks.
  • There are no data on the presence of Lumason in human milk, the effects on the breastfed infant, or the effects on milk production.
  • The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Lumason and any potential adverse effects on the breastfed infant from Lumason or from the underlying maternal condition.

QUESTION

In the U.S., 1 in every 4 deaths is caused by heart disease. See Answer

Summary

Lumason (sulfur hexafluoride lipid-type A microspheres) is an ultrasound contrast agent indicated for use in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms, and in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients. Serious side effects include serious cardiopulmonary reactions, including fatalities.

Treatment & Diagnosis

Medications & Supplements

Prevention & Wellness

Health Solutions From Our Sponsors

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Medically Reviewed on 3/5/2021
References
All sections courtesy of the U.S. Food and Drug Administration